Supplement for Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

Name: Supplement for Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials
Creator: Jonathan Silverberg
Published: 2024-05-13T06:56:17.470Z
Keywords: Dermatology, Atopic Dermatitis

Silverberg, Jonathan

doi:10.17632/g6455cpd93.1

Supplement for Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

Published: 13 May 2024| Version 1 | DOI: 10.17632/g6455cpd93.1

Contributor:

Jonathan Silverberg

Description

Supplemental materials for the article entitled, "Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.” Includes Supplemental Figures 1-4.

Supplement for Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

Description

Files

Categories

Licence